BioAdaptives, Inc. Brings Top Revolutionary Formulas Together in Wellness Introductory Offer

3 years ago

Responding to Consumers, Management Offers Cost-Effective Combination With Enhanced Synergistic Benefits LAS VEGAS, NV , June 29, 2022 (GLOBE NEWSWIRE)…

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia

3 years ago

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage…

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

3 years ago

AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM…

MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases

3 years ago

MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi…

InvestmentPitch Media Video Discusses Reliq Health, a Rapidly Growing Global Telemedicine Company, Signs 6 New Contracts with Physician Practices, Home Health Agencies and Skilled Nursing Facilities, adding more than 3,500 Patients to its Platform

3 years ago

VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global…

Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

3 years ago

    Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following…

MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases

3 years ago

MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi…

89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

3 years ago

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the…

Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care

3 years ago

The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide…